Charles Schiffer, MD, professor of Oncology and Medicine, Wayne State University, oncologist/hematologist, Barbara Ann Karmanos Cancer Institute, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia (CML).

Patients with CML who have had consecutively low or negative transcript levels for a number of years may be eligible to discontinue treatment with a TKI, says Schiffer. Patients who discontinue treatment are monitored closely via blood tests rather than bone marrow tests, Schiffer says. 

Utilizing blood tests, a patient’s polymerase chain reaction level can be monitored every month for the first 6 to 8 months after stopping treatment, says Schiffer. From then on, testing may decrease to every 2 or 3 months.

Some patients who discontinue treatment may develop TKI withdrawal syndrome, which manifests mainly as musculoskeletal aches, Schiffer says. Most often, this syndrome is managed with nonsteroidal anti-inflammatory drugs, but symptoms could worsen or become persistent. 

Notably, nearly all patients who relapse after stopping a TKI respond when therapy is reinitiated, as long as they’re appropriately monitored, concludes Schiffer. 

Videos

Charles Schiffer, MD, discusses factors to consider for TKI discontinuation in chronic myeloid leukemia.  



Charles Schiffer, MD

Articles

Dr. Schiffer on Factors to Consider for TKI Discontinuation in CML